All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Originally posted by @loseitwithannie on TikTok · 65s|Watch on TikTok
Full video transcriptClick to expand

Auto-generated transcript of @loseitwithannie's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.

  1. 0:00It's 24 hours after Moundjaro. If you know, you know.
  2. 0:09Yes, I have a jacket on. Him laying down.
  3. 0:15Entired all day. I have a headache. And it's just one of those days.
  4. 0:25This is why I recommend that you do your injection 24 hours prior to your scheduled day weekend.
  5. 0:34Because if you need to, you can just rest it out.
  6. 0:38I've had a biocare. I've eaten. I've had electrolytes. I've had papaya enzymes. I've had advil.
  7. 0:48And it's just one of those days. So, what have we learned?
  8. 0:54Even people on maintenance who've been on this medication for 20 months can have side effects.
  9. 1:02If we get to, we get to.

@loseitwithannie's Mounjaro side effects claim, fact-checked

Annie Del Mar

TikTok creator

1.1M viewsWatch on TikTok

Quick answer

Tirzepatide (Mounjaro, Zepbound) is a dual GIP and GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management. Adverse events including fatigue, nausea, and headache are documented throughout treatment in clinical trial data, not only during dose escalation. Patients on stable maintenance doses may still experience intermittent symptomatic episodes, and this pattern is reflected in both trial data from the SURMOUNT program and real-world post-market reports.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

GLP-1 social video fact-checksCompounded TirzepatideProvider discussion

Evidence signal

Source-backed review

Regulatory reality

Compounded Tirzepatide access requires the right clinical path

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 7 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For @loseitwithannie's Mounjaro side effects claim, fact-checked, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Provider decision path

Use local research to choose a safer review path

Direct answer

Compounded Tirzepatide is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.

Evidence check

Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.

Safety check

Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.

Next step

When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.

Claim path

Keep researching this tirzepatide video claims cluster

Best for searchers deciding whether tirzepatide claims are stronger, safer, or more relevant than semaglutide claims.

Page-specific review note

What this exact clip is really saying

This FormBlends review is specific to "@loseitwithannie's Mounjaro side effects claim, fact-checked" from Annie Del Mar. We read the clip as a GLP-1 social video fact-checks claim about Compounded Tirzepatide, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: Tirzepatide (Mounjaro, Zepbound) is a dual GIP and GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management.

The reason this review is not generic is the source wording and the canonical claim label "glp1 side effects can happen to anyone mounjaro zepbound." In this clip, the useful excerpt is: "It's 24 hours after Moundjaro." That wording changes the review because it points to Compounded Tirzepatide safety, access, evidence, and fit, not a one-size-fits-all protocol.

The source trail for this page is checked against Tirzepatide Once Weekly for the Treatment of Obesity (2022), Continued Treatment With Tirzepatide for Maintenance of Weight Reduction (2024), and Tirzepatide for Obesity Treatment and Diabetes Prevention (2025), plus the creator's own wording. Compounded Tirzepatide still needs an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.

Approximately 4-6% of tirzepatide users in SURMOUNT-1 discontinued due to adverse events even after reaching stable dosing, suggesting side effects are not universally self-resolving.
People who land here are usually comparing the Compounded Tirzepatide claim with [object Object].
The strongest next step is to compare the claim with FormBlends' Compounded Tirzepatide guide, evidence notes, and provider review path before acting.

Claim verdict

The useful answer behind this video

This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.

Claim being checked

Tirzepatide (Mounjaro, Zepbound) is a dual GIP and GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management.

FormBlends verdict

Compounded Tirzepatide safety, access, evidence, and fit

Evidence strength

Source-backed review with clinical or regulatory citations.

Patient-safe next step

Compare the claim with the Compounded Tirzepatide guide, safety notes, access rules, and a licensed-provider review.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • Tirzepatide (Mounjaro, Zepbound) is a dual GIP and GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management. Adverse events including fatigue, nausea, and headache are documented throughout treatment in clinical trial data, not only during dose escalation. Patients on stable maintenance doses may still experience intermittent symptomatic episodes, and this pattern is reflected in both trial data from the SURMOUNT program and real-world post-market reports.
  • SURMOUNT-1 (Jastreboff et al., 2022, NEJM) found GI adverse events persisted throughout 72 weeks of tirzepatide use, not just during the titration phase.
  • Approximately 4-6% of tirzepatide users in SURMOUNT-1 discontinued due to adverse events even after reaching stable dosing, suggesting side effects are not universally self-resolving.

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compounded Tirzepatide decisions still need source quality, legal access, and provider oversight checks.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against the Compounded Tirzepatide guide, cost path, safety notes, and provider review before acting.

Review Compounded Tirzepatide

What You'll Learn

  • SURMOUNT-1 (Jastreboff et al., 2022, NEJM) found GI adverse events persisted throughout 72 weeks of tirzepatide use, not just during the titration phase.
  • Approximately 4-6% of tirzepatide users in SURMOUNT-1 discontinued due to adverse events even after reaching stable dosing, suggesting side effects are not universally self-resolving.
  • Papaya enzyme supplements have no clinical trial evidence supporting their use for GLP-1 or tirzepatide-related nausea. They are not dangerous for most people, but they are not proven either.
  • NSAIDs like ibuprofen carry higher GI irritation risk when taken on a near-empty stomach. Acetaminophen is generally preferred for pain management when food intake is low.
  • The FDA label for tirzepatide lists nausea, fatigue, and headache as adverse reactions without specifying that they resolve after a defined treatment period.
  • Timing injections before lower-demand days is informal but reasonable harm-reduction advice that does not conflict with prescribing guidance.
  • Real-world data (Blonde et al., 2023, Diabetes, Obesity and Metabolism) confirms that adverse event patterns in clinical practice mirror trial findings, including ongoing intermittent symptoms in established users.

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.

What did @loseitwithannie actually say?

She's 24 hours post-injection and feeling rough. Fatigue, headache, general misery. Her advice: time your shot before a free weekend so you can rest if needed. Her main point is that "even people on maintenance who've been on this medication for 20 months can have side effects." She also lists what she tried to manage symptoms: hydration, electrolytes, papaya enzymes, and ibuprofen.

This is a firsthand account, not a medical recommendation. She's not telling you what dose to take or claiming tirzepatide cures anything. She's documenting a bad day and sharing a scheduling tip. That's a pretty narrow lane, and she mostly stays in it.

Does the science back this up?

Yes, the core claim holds. Side effects on GLP-1 and GIP/GLP-1 receptor agonists like tirzepatide are not a new-user-only problem. The evidence says so plainly.

The SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM) followed patients on tirzepatide for 72 weeks. Gastrointestinal adverse events were most common early but were still reported throughout the trial at all dose levels, including in participants who had been on stable doses for months. The trial did not suggest these effects resolve permanently after a titration period.

A 2023 real-world analysis published in Diabetes, Obesity and Metabolism (Blonde et al.) confirmed that nausea, fatigue, and headache remain reported adverse events even in long-term users. Intermittent flare-ups, not a clean plateau, appear to be the more accurate picture for a meaningful subset of patients.

Her scheduling advice, doing the injection before days when you can rest, is consistent with how many clinicians informally counsel patients. It is not an FDA recommendation, but it is reasonable harm-reduction logic.

What did they get wrong (or right)?

She got the main claim right. Long-term users can still have symptomatic days. That is accurate and worth saying out loud given how often the narrative online is "side effects go away after a few weeks."

The papaya enzyme recommendation deserves a closer look. Papain, the active enzyme in papaya supplements, is sometimes promoted for digestive discomfort, but there is no clinical evidence supporting its use specifically for GLP-1-related nausea or gastroparesis-adjacent symptoms. It is not dangerous for most people, but it is also not studied in this context. She presents it as part of her personal toolkit without claiming it is proven, which is a fair framing. Still, viewers may assume it is evidence-based when it is not.

Ibuprofen use on an empty or near-empty stomach, which is common when GLP-1 users are nauseated and eating little, carries real GI irritation risk. She does not mention this. It is a minor omission but worth noting for anyone following her routine.

What should you actually know?

Side effects from tirzepatide are not a one-time hurdle you clear during titration. For some patients, they resurface when doses are adjusted, when eating habits change, or seemingly at random. The SURMOUNT program data and post-market reporting both confirm this.

If you are managing side effects, the interventions with the most clinical support are small, low-fat meals, staying upright after eating, and staying hydrated. Electrolytes have indirect support through hydration management. Papaya enzymes and similar supplements do not have peer-reviewed backing for this specific use case.

NSAIDs like ibuprofen are worth using cautiously if you are already experiencing nausea or eating very little. Acetaminophen is generally considered the lower-risk option in that scenario. Talk to your prescriber before making that call.

Her broader point, that being on maintenance dose does not make you immune to hard days - is accurate, not alarmist, and more honest than a lot of content in this space.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

Annie Del Mar · TikTok creator

1.1M views on this video

Side effects can happen to anyone. #mounjaro #zepbound

Frequently asked questions

Quick answers based on this video and our medical team review.

What does the video say about surmount-1 (jastreboff et al., 2022, nejm) found gi adverse events?

SURMOUNT-1 (Jastreboff et al., 2022, NEJM) found GI adverse events persisted throughout 72 weeks of tirzepatide use, not just during the titration phase.

What does the video say about approximately 4-6% of tirzepatide users in surmount-1 discontinued due to?

Approximately 4-6% of tirzepatide users in SURMOUNT-1 discontinued due to adverse events even after reaching stable dosing, suggesting side effects are not universally self-resolving.

What does the video say about papaya enzyme supplements have no clinical trial evidence supporting their?

Papaya enzyme supplements have no clinical trial evidence supporting their use for GLP-1 or tirzepatide-related nausea. They are not dangerous for most people, but they are not proven either.

What does the video say about nsaids like ibuprofen carry higher gi irritation risk?

NSAIDs like ibuprofen carry higher GI irritation risk when taken on a near-empty stomach. Acetaminophen is generally preferred for pain management when food intake is low.

What does the video say about the fda label for tirzepatide lists nausea, fatigue,?

The FDA label for tirzepatide lists nausea, fatigue, and headache as adverse reactions without specifying that they resolve after a defined treatment period.

What does the video say about timing injections before lower-demand days?

Timing injections before lower-demand days is informal but reasonable harm-reduction advice that does not conflict with prescribing guidance.

Sources & references

Citations extracted from our medical team's review. Click any citation to search PubMed.

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by Annie Del Mar, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.